Axon Enterprise (NASDAQ:AXON) Price Target Raised to $755.00

Key Points

• JPMorgan Chase raised its price target on Axon to $755 (from $750) with an "overweight" rating — implying about a 77.7% upside — while the Street consensus target is roughly $722.69 and the consensus rating is "Moderate Buy."
• Axon reported Q1 revenue of about $807M (≈+34% Y/Y), beat EPS estimates, and raised full‑year revenue growth guidance to roughly 30–32%, driven by very strong AI revenue growth (~700% Y/Y) and software/services momentum.
• However, some analysts trimmed price targets and flagged margin/earnings pressure, and insiders sold roughly $7.1M of shares over the past three months, highlighting near‑term concerns on valuation and margins.

Axon Enterprise (NASDAQ:AXON - Get Free Report) had its price target upped by equities researchers at JPMorgan Chase & Co. from $750.00 to $755.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has an "overweight" rating on the biotechnology company's stock. JPMorgan Chase & Co.'s target price would indicate a potential upside of 77.70% from the company's previous close.

Other analysts have also issued research reports about the company. Barclays lowered their target price on Axon Enterprise from $702.00 to $682.00 and set an "overweight" rating for the company in a report on Wednesday, February 25th. Citigroup restated a "buy" rating on shares of Axon Enterprise in a research note on Wednesday, February 25th. TD Cowen dropped their price objective on Axon Enterprise from $950.00 to $825.00 and set a "buy" rating on the stock in a research report on Wednesday, April 8th. The Goldman Sachs Group set a $535.00 target price on Axon Enterprise in a research note on Thursday. Finally, Citizens Jmp reduced their target price on shares of Axon Enterprise from $825.00 to $700.00 and set a "market outperform" rating for the company in a report on Thursday. Sixteen research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Axon Enterprise has a consensus rating of "Moderate Buy" and a consensus target price of $722.69.

Axon Enterprise Stock Up 10.1%

Axon Enterprise stock traded up $39.02 during midday trading on Thursday, hitting $424.88. 1,860,802 shares of the company's stock were exchanged, compared to its average volume of 1,053,136. The company has a debt-to-equity ratio of 0.53, a quick ratio of 2.29 and a current ratio of 2.53. The company has a market cap of $34.23 billion, a PE ratio of 278.81, a P/E/G ratio of 8.12 and a beta of 1.44. The firm has a 50-day moving average of $452.24 and a two-hundred day moving average of $529.24. Axon Enterprise has a 12 month low of $339.01 and a 12 month high of $885.91.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last posted its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 EPS for the quarter, beating the consensus estimate of $1.60 by $0.55. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The business had revenue of $796.72 million during the quarter, compared to analyst estimates of $755.29 million. During the same quarter in the previous year, the business posted $2.08 EPS. The company's quarterly revenue was up 38.5% compared to the same quarter last year. As a group, analysts expect that Axon Enterprise will post 1.41 earnings per share for the current fiscal year.

Insider Transactions at Axon Enterprise

In other news, Director Erika Nardini sold 198 shares of the firm's stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $506.58, for a total value of $100,302.84. Following the completion of the sale, the director owned 1,946 shares of the company's stock, valued at $985,804.68. This trade represents a 9.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jeri Williams sold 157 shares of the company's stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $490.00, for a total value of $76,930.00. Following the transaction, the director directly owned 1,159 shares in the company, valued at $567,910. This represents a 11.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 13,855 shares of company stock worth $7,109,828. 4.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Axon Enterprise

A number of institutional investors have recently bought and sold shares of AXON. Baillie Gifford & Co. raised its holdings in shares of Axon Enterprise by 1,198.7% in the fourth quarter. Baillie Gifford & Co. now owns 1,642,578 shares of the biotechnology company's stock worth $932,869,000 after buying an additional 1,516,099 shares during the last quarter. Edgewood Management LLC acquired a new position in shares of Axon Enterprise in the 4th quarter valued at $846,516,000. Wellington Management Group LLP raised its stake in Axon Enterprise by 326.9% in the 4th quarter. Wellington Management Group LLP now owns 1,539,738 shares of the biotechnology company's stock worth $874,463,000 after acquiring an additional 1,179,038 shares during the last quarter. Norges Bank purchased a new position in Axon Enterprise in the 4th quarter worth $515,764,000. Finally, Vanguard Group Inc. lifted its position in Axon Enterprise by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company's stock worth $6,684,217,000 after acquiring an additional 376,904 shares during the period. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Axon Enterprise News Roundup

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q1 revenue and guidance lift — Axon reported Q1 revenue of about $807M (+33.7% Y/Y) and raised its full‑year revenue growth outlook to roughly 30–32%, citing strong software and device demand. This beat and the guidance raise are the primary positive catalysts. Axon reports Q1 2026 revenue
• Positive Sentiment: AI and product momentum — Management highlighted very strong AI revenue (up ~700% Y/Y), software & services growth (~35% Y/Y), and large gains in counter‑drone sales, underpinning faster recurring revenue and long‑term ARR expansion. Axon Raises Guidance With AI Revenue Up 700%
• Positive Sentiment: Analyst buy support — Multiple firms reiterated or maintained Buy ratings (William Blair, Needham) and some analysts kept sizable price targets (e.g., Needham $600), signaling continued sell‑side confidence in Axon’s growth trajectory. Axon Earns Buy Rating
• Neutral Sentiment: Price target trims but still bullish — Citizens Jmp lowered its PT from $825 to $700 (still “market outperform”) and Piper Sandler trimmed its PT to $674 (still “overweight”). These cuts reduce upside expectations but left ratings intact, so they’re only a modest drag. Citizens Jmp price target cut
• Negative Sentiment: Margin/earnings pressure — Reports flagged an EPS miss (tariff‑driven margin headwinds and a small EPS shortfall vs some estimates), which tempers the headline beat and is the primary near‑term risk to multiple‑expansion. AXON Q1 Earnings Miss Estimates
• Negative Sentiment: Short‑term sell‑side reaction mixed — Some coverage noted shares “slipped” in places despite the beat, reflecting investor focus on margins, valuation, and the recent YTD share price decline. Axon Shares Slip Despite Q1 Results

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company's hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.